EP1474436B1 - Procede pour la preparation du propionate de fluticasone,notamment de la forme polymorphe 1 - Google Patents

Procede pour la preparation du propionate de fluticasone,notamment de la forme polymorphe 1 Download PDF

Info

Publication number
EP1474436B1
EP1474436B1 EP03704541A EP03704541A EP1474436B1 EP 1474436 B1 EP1474436 B1 EP 1474436B1 EP 03704541 A EP03704541 A EP 03704541A EP 03704541 A EP03704541 A EP 03704541A EP 1474436 B1 EP1474436 B1 EP 1474436B1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
solution
fluticasone propionate
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP03704541A
Other languages
German (de)
English (en)
Other versions
EP1474436A2 (fr
Inventor
Steven John Coote
Rosalyn Kay Nice
Mark David Wipperman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of EP1474436A2 publication Critical patent/EP1474436A2/fr
Application granted granted Critical
Publication of EP1474436B1 publication Critical patent/EP1474436B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • This invention relates to a novel process for preparing fluticasone propionate, especially fluticasone propionate as crystalline Form 1 polymorph.
  • Fluticasone propionate is a corticosteroid of the androstane family which has potent anti-inflammatory activity and is widely accepted as a useful therapy for the treatment of inflammatory and allergic conditions such as rhinitis, asthma and chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • Fluticasone propionate and methods for preparing it were first described in British Patent 2088877 (see Example 14 thereof).
  • a crystalline form of fluticasone propionate, designated polymorphic Form 1 may be obtained by dissolving the crude product (obtained eg as described in GB 2088877 ) in ethyl acetate and then recrystallising. Standard spray-drying processes have also been shown to lead to the Form 1 of fluticasone propionate.
  • Phillips et al (1994) J Med Chem, 37, 3717-3729 also describes the direct recrystallisation of fluticasone propionate from acetone.
  • WO98/17676 disclosed a new polymorphic form of fluticasone propionate, designated polymorphic Form 2, which could be obtained by supercritical fluid techniques. Modification of the supercritical conditions could also lead to generation of the Form 1 polymorph.
  • Example conditions described in WO98/17676 for preparing Form 1 included co-introducing carbon dioxide and a solution of fluticasone propionate dissolved in acetone via a co-axial nozzle into a particle generation vessel.
  • Polymorphic Forms 1 and 2 of fluticasone propionate may be distinguished by their XRPD profiles and unit cell dimensions. For example crystalline polymorphic Form 1 has a monoclinic crystal structure with characteristics as follows:
  • crystalline Polymorphic Form 2 has an orthorhombic crystal structure with characteristics as follows:
  • main process for preparing fluticasone propionate as crystalline polymorphic Form 1 which comprises mixing a solution of fluticasone propionate in a non-solvating organic liquid solvent with a non-solvating organic liquid anti-solvent thereby causing fluticasone propionate as crystalline polymorphic Form 1 to crystallise out of the solution.
  • the process is performed at ambient atmospheric pressure such that the solvent and anti-solvent are liquids at ambient atmospheric pressure.
  • the non-solvating organic liquid solvent and non-solvating organic liquid anti-solvent will be liquids which do not have a tendency to form crystalline solvates with fluticasone propionate.
  • the non-solvating organic liquid solvent is selected from methyl acetate, ethyl acetate and pentanone, for example pentan-3-one, especially ethyl acetate, more especially pentan-3-one.
  • the non-solvating organic liquid anti-solvent is selected from toluene, isooctane or hexane, particularly hexane, more particularly toluene.
  • water is not an organic liquid anti-solvent.
  • the process according to the invention is advantageous over prior art processes, for example: it can be performed at ambient pressure without need for use of elaborate apparatus eg to enable use of supercritical carbon dioxide, or use of ultrasound, or to create vortex mixing conditions. Also in one aspect of the invention it permits fluticasone propionate to be prepared as crystalline polymorph Form 1 directly from precursors of fluticasone propionate without need for fluticasone propionate in subtantially pure form to be isolated as an intermediate step in the process. Thus it has economic and other processing advantages since the number of steps in the overall synthesis may be reduced.
  • process (a) comprises reacting a compound of formula (II) or a salt thereof with a compound of formula LCH 2 F, where L represents a leaving group mesyl, tosyl or halogen, eg Cl, Br or I.
  • L represents halogen, particularly Br.
  • Advantageous conditions for performing this step comprise combining the compound of formula (II) or a salt thereof optionally in the presence of a phase-transfer catalyst, a water-immiscible non-solvating organic solvent and water.
  • a free acid of compound of formula (II) is employed, then a base should also be included to remove the -SH proton.
  • Suitable bases include tri-n-propylamine, tributylamine, sodium bicarbonate, triethylamine, diisopropylethylamine and the like.
  • the water immiscible non-solvating organic solvent is a non-solvating organic solvent selected from the list mentioned above.
  • the non-solvating liquid organic solvent used in the main process is preferably the same solvent i.e. it is immiscible with water, and is most preferably ethyl acetate, even moreso, pentan-3-one. This avoids the need for an isolation step.
  • substantially immiscible solvents provide two phases when the solvents are mixed and have a low level of solubility of one in the other eg the solubility of one solvent in the other solvent is less than 10% w/w, especially 5% w/w.
  • phase-transfer catalysts examples include tetrabutylammonium bromide, tetrabutylammonium chloride, benzyltributylammonium bromide, benzyltributylammonium chloride, benzyltriethylammonium bromide, methyltributylammonium chloride and methyltrioctylammonium chloride, preferably benzyltributylammonium chloride, benzyltriethylammonium bromide, especially benzyltributylammonium chloride.
  • phase-transfer catalyst will be employed in an amount of 1-15mol% based on compound of formula (II), especially 5-12%, particularly around 10%.
  • advantages of this process include the fact that the presence of a phase transfer catalyst in the reaction mixture results in a significantly faster reaction rate relative to its absence.
  • advantages of the invention include the fact that fluticasone propionate as crystalline polymorph Form 1 may be isolated directly from the alkylation solvent without need for an intermediate isolation step.
  • a further advantage is that the use of methyl ethyl ketone or addition of methyl ethyl ketone to ethyl acetate increases the rate of reaction.
  • the fluticasone propionate product present in an organic phase following process (a) is preferably increased in purity by washing firstly with aqueous acid eg dilute HCl in order to remove amine compounds such as triethylamine and diisopropylethylamine (which may be present following process (b) described below) and then with aqueous base eg sodium bicarbonate in order to remove any unreacted precursor compound of formula (II).
  • the washed organic layer (which may be separated from the more dense aqueous layer by conventional means, eg by running it off) is preferably concentrated by distillation (optionally under reduced pressure) before being treated with the organic anti-solvent according to the main process described above.
  • the invention provides a process for preparing fluticasone propionate as crystalline polymorphic Form 1 which comprises
  • compounds of formula (II) may be prepared by reacting a compound of formula (III) with an activated derivative of propionic acid eg propionyl chloride.
  • the activated derivative of propionic acid will generally be employed in at least 2 times molar quantity relative to the compound of formula (III) since one mole of the reagent will react with the thioacid moiety and needs to be removed eg by reaction with an amine such as diethylamine.
  • process (b) for preparing a compound of formula (II) or a salt thereof which comprises:
  • examples of activated derivatives of propionic acid include activated esters or preferably a propionyl halide such as propionyl chloride.
  • This reaction is conventionally performed in the presence of an unreactive organic base such as a triC 1-4 alkylamine eg triethylamine, tripropylamine, or tributylamine especially triethylamine, more especially tri-n-propylamine.
  • Solvents for this process include substantially water immiscible organic liquid solvents such as ethyl acetate or methyl acetate or water miscible organic liquid solvents such as acetone, N,N-dimethylformamide or N,N-dimethylacetamide, especially acetone.
  • examples of organic primary or secondary amine base capable of forming a water soluble propanamide include amines which are more polar than diethylamine eg an alcoholamine, eg diethanolamine, or a diamine for example N-methylpiperazine.
  • N-methylpiperazine is employed. It may be convenient to dissolve the amine in small volume of an organic solvent such as methanol.
  • the aqueous washing steps may suitably be performed with water or dilute acid eg dilute HCl or acetic acid. In these steps, the more dense aqueous layer may be separated from the organic layer by conventional techniques eg running off under gravity.
  • steps (a) and (b) are performed at reduced temperature eg 0-5 °C.
  • Step (II) of this process is a substantially water immiscible organic liquid solvent, more preferably the same solvent as is used in step (a), and even more preferably the same solvent as is used in the main process as well.
  • the solvent used in step (a) is most preferably ethyl acetate, even more preferably pentan-3-one.
  • the compound of formula (II) may advantageously be isolated in the form of a solid crystalline salt rather than the free compound of formula (II).
  • the preferred salt is formed with a base such as diisopropylethylamine, triethylamine, 2,6-dimethylpyridine, N-ethylpiperidine or with potassium especially triethylamine.
  • Such salt forms of compound of formula (II) are more stable, more readily filtered and dried and can be isolated in higher purity than the free compound of formula (II).
  • the most preferred salt is the salt formed with triethylamine.
  • the potassium salt is also of interest.
  • the compound of formula (II) may advantageously be isolated with higher efficiency than by means of prior art processes.
  • the process for the preparation of the compound of formula (II) disclosed in G.H. Phillips et al (1994) J Med Chem 37, 3717-3729 involves the isolation of the product from an acetone/water system. The product so prepared is extremely difficult to filter.
  • the compound of formula (II) when prepared in accordance with the process as defined above, is far easier to filter.
  • the process of the present invention may also offer improvements in purity.
  • One such process comprises treating the organic phase containing the compound of formula (II) with a base as to precipitate the compound of formula (II) in the form of a solid crystalline salt.
  • Example bases include triethylamine, 2,6-dimethylpyridine, N-ethylpiperidine or a basic potassium salt eg potassium hydrogen carbonate.
  • the imidazole salt of the compound of formula (III) may be prepared, isolated, and stored for subsequent use in the process for the preparation of the compound of formula (II) as described herein.
  • the imidazole salt of the compound of formula (III) may be prepared and used directly as a wet cake in the subsequent conversion to a compound of formula (II) thus avoiding the need to dry the imidazole salt before further reaction.
  • the compound of formula (IV) and between 1.1 and 2.5 equivalents, suitable 1.8 equivalents, of carbonyldiimidazole are stirred in a suitable solvent, for example ethyl acetate containing between 0 and 2 vol., suitably 0.5 vol., of N,N-dimethylformamide, at a suitable temperature, for example 18-20°C, for a suitable period of time, for example one hour.
  • a suitable solvent for example ethyl acetate containing between 0 and 2 vol., suitably 0.5 vol., of N,N-dimethylformamide
  • the resulting suspension is cooled to a suitable temperature, for example -5 to 5°C, suitably -3 to 3°C, and hydrogen sulphide gas introduced over a period of 15-60 minutes, suitably 20-30 minutes, while the suspension is stirred.
  • the reaction mixture is stirred for a further period of about 30 minutes at -5 to 5°C, warmed to about 10°C over a period of about 20 minutes and stirred at 6-12°C for 90-120 minutes.
  • the product is then isolated by filtration, at a suitable temperature, suitable 5-25°C, preferably 10-15°C, washed with a suitable solvent, for example ethyl acetate, and dried in vacuo to yield the imidazole salt of the compound of formula (III).
  • the compound of formula (III) is a monobasic acid and therefore would be expected to form an imidazole salt wherein the stoichiometry of the imidazole salting moiety to the compound of formula (III) is approximately 1:1.
  • the stoichiometry of the imidazole salting moiety to the compound of formula (III) may be up to and including 4:1.
  • imidazole salt encompasses imidazole salts of the compound of formula (III) and association compounds of the compound of formula (III) and imidazole wherein the stoichiometry of the imidazole moiety to the compound of formula (III) is up to and including 4:1, for example 1:1 to 4:1, suitably 1.8:1 to 2.5:1.
  • An example of a typical stoichiometry is 2:1. It will be understood that, in the context of stoichiometric values, exact numerical values are to be construed to include nominal variations therefrom.
  • the compound of formula (III) used in the processes described herein is used as an imidazole salt.
  • a process for the preparation of fluticasone propionate, from a compound of formula (IV) without isolation of intermediate compounds comprises the preparation of the compound of formula (III) or a salt thereof from the compound of formula (IV), followed by in situ conversion of the compound of formula (III) to the compound of formula (II), followed by in situ conversion of the compound of formula (II) to fluticasone propionate.
  • suitable solvents for example a mixture of ethyl acetate and N,N-dimethylformamide are added sequentially to an intimate mixture of the compound of formula (IV) and N,N'-carbonyldiimidazole (6.3g).
  • the resulting suspension is stirred at a suitable temperature, for example 18-20°C for about one hour to give a pale yellow solution.
  • the solution is then cooled to -5 to 25°C, suitably -3 to 3°C and hydrogen sulfide bubbled through the solution over 15-60 minutes, suitably 20-30 minutes maintaining the contents at 12 ⁇ 2°C.
  • the resulting suspension is stirred at 12 ⁇ 2°C for a further 90-120 minutes and then placed under moderate vacuum with a slow nitrogen bleed and stirred vigorously for about one hour.
  • the vacuum is then released and the vessel purged with an inert gas, suitably nitrogen.
  • a suitable solvent for example 3-pentanone is then added and the slurry washed with aqueous mineral acid, for example 2M hydrochloric acid and then water.
  • the resulting solution is cooled to 0-5°C and tripropylamine added over 2 minutes ensuring that the reaction temperature remains at 0-5°C.
  • the solution is stirred at 0-5°C and propionyl chloride added over about 5 minutes keeping the reaction at 0-5°C.
  • the solution was then allowed to warm to about 10°C and stirred at this temperature for 90-120 minutes.
  • the solution is then cooled to 0-5°C and 1-methylpiperazine added keeping the reaction at 0-5°C.
  • the solution is stirred at 0-5°C for about 20 minutes and then bromofluoromethane added in a single portion.
  • the solution is allowed to warm to ambient temperature and stirred for 16 hours.
  • the solution is then washed sequentially with dilute mineral acid, for example 1M HCl, water, aqueous base, for example 1 % NaHCO 3 and water and then concentrated by atmospheric distillation to about 80ml and then cooled to 90°C.
  • the solution is seeded with fluticasone propionate (Form I) and then a suitable antisolvent, for example toluene added keeping the slurry at about 90°C.
  • a suitable antisolvent for example toluene added keeping the slurry at about 90°C.
  • the slurry is then concentrated by atmospheric distillation to about 8 vol.
  • the slurry is then cooled to about 90°C.
  • Toluene is then added over 20 minutes keeping the slurry at about 90°C.
  • the slurry is then cooled to about 10°C over 90 minutes, aged at about 10°C for about one hour and then filtered.
  • the cake is washed with a suitable solvent, for example a mixture of 3-pentanone and toluene (1:4) and sucked dry.
  • the solid is then dried by conventional means.
  • LCMS was conducted on a 25cm X 0.46cm Inertsil ODS-2, 5 ⁇ m column eluting with 58% ⁇ 0.1% Formic acid in 3% methanol (aqueous) ⁇ (solvent A), and 42% ⁇ 0.1% Formic acid in 3% methanol (acetonitrile) ⁇ (solvent B), using the following elution gradient 0-40 min 42%B, 40-60 min 53%B, 60-75 min 87%B, 75-85 min 42%B at a flow rate of 1 ml/min.
  • the mass spectra were recorded on a HP LC/MSD spectrometer using electrospray positive and negative mode (ES+ve and ES-ve)
  • Liquid Chromatography (Method A) was conducted on a 25 cm X 0.46 cm ID packed with 5 ⁇ m Inertsil ODS-2 column eluting with the following acidified mobile phases:
  • Liquid Chromatography (Method B) was conducted on a Stainless steel 5 ⁇ m Octyl 20cm x 0.46cm id column eluting with the following acidified mobile phases:
  • the resultant suspension is further cooled to -3°C to -7°C and treated with propionyl chloride (6.2 ml) over approximately 30 minutes, maintaining the reaction temperature at -5°C to +2°C.
  • Acetone (2.8 ml) is added as a line wash and the solution is stirred at -5°C to +2°C for a further 2 hours.
  • the resultant suspension is further cooled to -3°C to -7°C and treated with diethanolamine (23.8 ml) in methanol (20 ml) over approximately 30 minutes, maintaining the temperature at -5°C to +2°C.
  • Acetone (2.8 ml) is added as a line wash and the solution is stirred at -5°C to +2°C for a further 30 minutes.
  • the mixture is quenched into water (135 ml) maintaining the temperature at -5°C to +5°C.
  • Acetone (5.6 ml) is added as a line wash and the mixture is cooled to 0°C to 5°C.
  • Concentrated hydrochloric acid (65 ml) is added over one to two hours maintaining the temperature in the range of 0°C to 5°C followed by addition of water (125 ml) maintaining the temperature at ⁇ 5°C.
  • the mixture is stirred at 0°C to 5°C for 15 minutes, the product is filtered off, washed with water and dried under vacuum at approximately 45°C for 18 hours to give the title compound as a white to off white solid (7.91 g, 99.5 %).
  • Example 1 6 ⁇ . 9 ⁇ -Difluoro-17 ⁇ -(1-oxopropoxy)-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo-androsta-1,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester (using ethyl acetate as solvent and hexane as anti-solvent)
  • Example 2 6 ⁇ , 9 ⁇ -Difluoro-17 ⁇ -(1-oxopropoxy)-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo-androsta-1,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester (using ethyl acetate as solvent and toluene as anti-solvent)
  • Example 3 6 ⁇ , 9 ⁇ -Difluoro-17 ⁇ -(1-oxopropoxy)-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo-androsta-1,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester (using ethyl acetate as solvent and iso-octane as anti-solvent)
  • Example 4 6 ⁇ , 9 ⁇ -Difluoro-17 ⁇ -(1-oxopropoxy)-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo-androsta-1,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester (using methyl acetate as solvent and toluene as anti-solvent)
  • Example 5 6 ⁇ , 9 ⁇ -Difluoro-17 ⁇ -(1-oxonropoxy)-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo-androsta-1,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester (using ethyl acetate as solvent and hexane as anti-solvent)
  • the mixture is warmed to 20°C over 2-3 hrs and the resultant suspension is sequentially washed with 0.5M hydrochloric acid (23 ml), 1 %w/w aqueous sodium bicarbonate solution (3 x 23 ml) and water (2 x 23 ml).
  • the organic layer is separated and the aqueous layer is optionally back extracted with ethyl acetate (30 ml).
  • the combined organic layers are distilled to an approximate volume of 22 ml and further ethyl acetate (7 ml) is added.
  • the mixture is cooled to approximately 20 °C, hexane (42 ml) is added over at least 30 minutes and the mixture is aged at 20 °C for 15 minutes.
  • Example 6 6 ⁇ , 9 ⁇ -Difluoro-17 ⁇ -(1-oxopropoxy)-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo-androsta-1,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester (using ethyl acetate as solvent and toluene as anti-solvent)
  • the mixture is warmed to 20°C over 2-3 hrs and the resultant suspension is sequentially washed with 0.5M hydrochloric acid (23 ml), 1 %w/w aqueous sodium bicarbonate solution (3 x 23 ml) and water (2 x 23 ml).
  • the organic layer is separated and the aqueous layer is optionally back extracted with ethyl acetate (30 ml).
  • the combined organic layers are distilled to an approximate volume of 22 ml and toluene (54 ml) is added.
  • the reaction mixture is further distilled to a total reaction volume of approximately 22ml.
  • Example 7 6 ⁇ , 9 ⁇ -Ditluoro-17 ⁇ -(1-oxopropoxy)-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo-androsta-1,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester ester (using methyl acetate as solvent and iso-octane as anti-solvent)
  • the mixture is warmed to 20°C over 2-3 hrs and the resultant suspension is sequentially washed with 0.5M hydrochloric acid (23 ml), 1 %w/w aqueous sodium bicarbonate solution (3 x 23 ml) and water (2 x 23 ml).
  • the organic layer is separated and the aqueous layer is optionally back extracted with ethyl acetate (30 ml).
  • the combined organic layers are distilled to an approximate volume of 22 ml and treated with iso-octane (54ml) over at least 30 minutes maintaining a temperature of approximately 20 °C.
  • the mixture is further distilled to a total reaction volume of approximately 22ml, cooled to approximately 10 °C and aged at this temperature for at least 30 minutes.
  • Example 8 6 ⁇ , 9 ⁇ -Ditluoro-17 ⁇ -(1-oxopropoxy)-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo-androsta-1,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester (using a single solvent to avoid isolation of intermediate 6 ⁇ , 9 ⁇ -difluoro-17 ⁇ -(1-oxopropoxy)-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo-androsta-1,4-diene-17 ⁇ -carbothioic acid)
  • the resultant suspension is further cooled to -3 °C to -7 °C and treated with propionyl chloride (6.2 ml) over approximately 30 minutes, maintaining the temperature at -5 °C to +2 °C.
  • Ethyl acetate (5 ml) is added as a line wash and the solution is stirred at -5 °C to +2 °C for a further 2 hours.
  • the resultant suspension is further cooled to -3°C to -7°C and treated with diethanolamine (23.8 ml) in methanol (20 ml) over approximately 30 minutes, maintaining the temperature at -5 °C to +2 °C.
  • Ethyl acetate (5 ml) is added as a line wash and the solution is stirred at -5°C to +2 °C for a further 30 minutes.
  • Acetic acid 25 ml is added maintaining the temperature in the range of -5 °C to +2 °C over approximately 10 minutes and the resultant suspension is aged at -5 °C to +5 °C for at least 10 minutes.
  • Water (30 ml) is added over approximately 10 minutes maintaining the temperature in the range of -5°C to +2°C and the organic phase is separated and washed with water (3 x 50 ml).
  • aqueous phases are optionally back extracted with ethyl acetate (120 ml) at -5 °C to +2 °C and the combined organic phases are concentrated to approximately 45 vol. by vacuum distillation (below 10 °C).
  • ethyl acetate 120 ml
  • the combined organic phases are concentrated to approximately 45 vol. by vacuum distillation (below 10 °C).
  • Approximately one half of the resultant solution is treated with water (13.5 ml), benzyltributylammonium chloride (0.37g) and triethylamine (1.3 ml) and the mixture is cooled to 5 °C.
  • Bromofluoromethane 0.5 ml is added maintaining a reaction temperature of approximately 5°C.
  • the mixture is warmed to 20°C over 2-3 hrs and the resultant suspension is sequentially washed with 0.5M hydrochloric acid (23 ml), 1 %w/w aqueous sodium bicarbonate solution (3 x 23 ml) and water (2 x 23 ml).
  • the organic layer is separated and the aqueous layer is back extracted with ethyl acetate (30 ml).
  • the combined organic layers are distilled to an approximate volume of 22 ml and further ethyl acetate (7 ml) is added.
  • the mixture is cooled to approximately 20 °C, hexane (42 ml) is added over at least 30 minutes and the mixture is aged at 20 °C for 15 minutes.
  • the resultant precipitate is collected by filtration, washed with 1:4 ethyl acetate/hexane (3 x 5 ml) and dried at approximately 50 °C for 18 hours to give the title compound as a white solid (3.54g, 95.7%).
  • a solution of 6 ⁇ , 9 ⁇ -difluoro-11 ⁇ ,17 ⁇ -dihydroxy-16 ⁇ -methyl-3-oxo-androsta-1,4-diene-17 ⁇ -carbothioic acid (10g) in acetone (125 ml) is cooled to approximately -5 °C and treated at 0 to -5 °C with triethylamine (16 ml) over approximately 15 minutes.
  • the suspension is treated with propionyl chloride (8.5 ml) over approximately 90 minutes, maintaining the temperature at -5 °C to 0 °C and the solution is stirred at -5 °C to 0 °C for a further 2 hours.
  • the batch is stirred at 0 ⁇ 3°C for 30 minutes, warmed to 9°C over 20 minutes and stirred at 9 ⁇ 3°C for a total of 100 minutes.
  • the product is collected by filtration (Whatman 54 paper) and the cake washed with ethyl acetate (2 x 105 ml). The product is dried under vacuum at approximately 20°C for 20 hours to give the title compound as a white to pale purple solid (47.7g, 98.5%th).
  • solvent wet cakes of 6 ⁇ 9 ⁇ -difluoro-11 ⁇ 17 ⁇ -dihydroxy-16 ⁇ -methyl-3-oxo-androsta-1,4-diene-17 ⁇ -carbothioic acid imidazole salt (rather than dried solids) can be used as inputs to the above acidification procedures.
  • Example 12 6 ⁇ ,9 ⁇ -Difluoro-17 ⁇ -(1-oxopropoxy)-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxoandrosta-1,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester
  • the solution was then allowed to warm to 12°C and stirred at 12 ⁇ 2°C for 90 minutes.
  • the solution was then cooled to 3°C and 1-methylpiperazine (5.1 ml) was added keeping the reaction at 3 ⁇ 2°C.
  • the solution was stirred at 3 ⁇ 2°C for 20 minutes and then bromofluoromethane (1.4ml) was added in a single portion.
  • the solution was allowed to warm to 18°C and stirred at 18 ⁇ 2°C for 16 hours.
  • the solution was then washed sequentially with 1M HCl (60ml), water (60ml), 1% NaHCO 3 (60ml) and water (60ml) and then concentrated by atmospheric distillation to about 80ml and then cooled to 90°C.
  • the solution was seeded with the title compound (0.05g) and then toluene (120ml) was added over 20 minutes keeping the slurry at 87 ⁇ 3°C.
  • the slurry was then concentrated by atmospheric distillation to about 80ml and then cooled to 90°C.
  • Toluene (120ml) was then added over 20 minutes keeping the slurry at 87 ⁇ 3°C.
  • the slurry was then cooled to 10°C over 90 minutes, aged at 10 ⁇ 3°C for 60 minutes and then filtered.
  • the cake was washed with 3-pentanone : toluene (1:4, 2x20ml) and sucked dry.
  • the solid was dried in a vacuum oven at 50°C for 16 hours to give the title compound as a white acicular solid (8.7g, 69%th).
  • Example 13 6 ⁇ , 9 ⁇ -Difluoro-17 ⁇ -(1-oxopropoxy)-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxoandrosta-1,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester
  • Ethyl acetate (100ml) and N,N-dimethylformamide (5ml) were added sequentially to an intimate mixture of 6 ⁇ , 9 ⁇ -difluoro-17 ⁇ -(1-oxopropoxy)-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxoandrosta-1,4-diene-17 ⁇ -carboxylic acid (10.0g) and N,N'-carbonyldiimidazole (6.3g).
  • the resulting suspension was stirred at 18-20°C for 50 minutes to give afford a pale yellow solution.
  • the solution was cooled to 10°C and hydrogen sulfide (2.2g) was bubbled through the solution over 25 minutes maintaining the contents at 12 ⁇ 2°C.
  • the resulting suspension was stirred at 12 ⁇ 2°C for a further 90 minutes and then placed under moderate vacuum (300-350mbar) with a slow nitrogen bleed and stirred vigorously for 50 minutes. The vacuum was then released and the vessel was purged with nitrogen. 3-Pentanone (150ml) was then added and the slurry was washed with 2M hydrochloric acid (60ml) and then water (60ml). The resulting solution was cooled to 3°C and tripropylamine (14.0ml) was added over 2 minutes ensuring reaction remained at 3 ⁇ 2°C. The solution was stirred at 3 ⁇ 2°C and propionyl chloride (5.3ml) was added over 5 minutes keeping reaction at 3 ⁇ 2°C.
  • the solution was then allowed to warm to 10°C and stirred at 12 ⁇ 2°C for 90 minutes.
  • the solution was then cooled to 3°C and 1-methylpiperazine (5.1 ml) was added keeping the reaction at 3 ⁇ 2°C.
  • the solution was stirred at 3 ⁇ 2°C for 20 minutes and then bromofluoromethane (1.4ml) was added in a single portion.
  • the solution was allowed to warm to 18°C and stirred at 18 ⁇ 2°C for 16 hours.
  • the solution was then washed sequentially with 1M HCl (60ml), water (60ml), 1% NaHCO 3 (60ml) and water (60ml) and then concentrated by atmospheric distillation to about 80ml and then cooled to 90°C.
  • Example 14 6 ⁇ , 9 ⁇ -Difluoro-17 ⁇ -(1-oxopropoky)-11 ⁇ -hydroxy-16 ⁇ -methyl-3-oxo-androsta-1,4-diene-17 ⁇ -carbothioic acid S-fluoromethyl ester (using pentan-3-one as solvent and toluene as anti-solvent)
  • the resulting suspension was concentrated by atmospheric distillation to about 90ml, cooled to 85°C and then toluene (95ml) was added over 20 minutes maintaining the mixture at 85 ⁇ 3°C.
  • the slurry was then aged at 85 ⁇ 3°C for 15 minutes and then cooled to 10°C over 90 minutes.
  • the slurry was aged at 12 ⁇ 3°C for 30 minutes and then filtered.
  • the cake was washed with pentan-3-one : toluene (1:3, 2x20ml) and sucked dry.
  • the solid was dried in a vacuum oven at 50°C for 4 hours to give the title compound as a white acicular solid (9.02g, 98%th).
  • NMR analysis revealed no solvation of the product and XRPD analysis confirmed the product as polymorph Form 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (11)

  1. Procédé de préparation du propionate de fluticasone sous la forme polymorphe cristalline 1, qui comprend le mélange d'une solution de propionate de fluticasone dans un solvant liquide organique non solvatant choisi parmi l'acétate de méthyle, l'acétate d'éthyle et la pentanone, avec un antisolvant liquide organique non solvatant choisi parmi le toluène, l'iso-octane et l'hexane, provoquant ainsi la cristallisation de la forme polymorphe cristalline 1 à partir de la solution, où le procédé est réalisé à la pression atmosphérique ambiante.
  2. Procédé selon la revendication 1, dans lequel le solvant liquide organiqus non solvatant est la pentan-3-one.
  3. Procédé selon la revendication 1 ou la revendication 2 où l'antisolvant liquide organique non solvatant est le toluène.
  4. Procédé selon la revendication 1, dans lequel la solution de propionate de fluticasone dans le solvant liquide organique non solvatant est préparée par les étapes suivantes :
    (a) la réaction d'un composé de formule (II)
    Figure imgb0015
     ou d'un sel de celui-ci avec un composé de formule LCH2F dans laquelle L représente un groupe libérable éventuellement en présence d'un catalyseur de transfert de phase, d'un solvant liquide organique non solvatant non miscible à l'eau choisi parmi l'acétate de méthyle, l'acétate d'éthyle et la pentanone et d'eau ;
    (b) l'augmentation éventuelle de la pureté du propionate de fluticasone dans la couche organique en réalisant une ou plusieurs étapes de lavage aqueux ;
    (c) la séparation de la couche organique de la couche aqueuse et la concentration éventuelle du propionate de fluticasone dans la couche organique.
  5. Procédé selon la revendication 4, dans lequel L représente un atome d'halogène.
  6. Procédé selon la revendication 4 ou 5, dans lequel le solvant liquide organique non miscible à l'eau est la pentan-3-one.
  7. Procédé selon l'une quelconque des revendications 4 à 6, dans lequel le composé de formule (II) ou un sel de celui-ci est préparé par un procédé comprenant :
    (a) la réaction d'un composé de formule (III)
    Figure imgb0016
     avec un dérivé activé de l'acide propionique dans une quantité d'au moins 1,3 mole du dérivé activé par mole de composé de formule (III) ; et
    (b) l'élimination du radical propionyl lié à un atome de soufre de tout composé de formule (IIA)
    Figure imgb0017
     ainsi formé par la réaction du produit de l'étape (a) avec une base organique d'amine primaire ou secondaire capable de former un propanamide soluble dans l'eau qui peut être ensuite éliminé par une ou plusieurs étapes de lavage aqueux.
  8. Procédé selon la revendication 7, dans lequel le procédé (a) est réalisé en présence de solvant liquide organique pratiquement non miscible à l'eau.
  9. Procédé selon la revendication 8, dans lequel le solvant est la pentan-3-one.
  10. Procédé selon l'une quelconque des revendications 7 à 9, dans lequel le composé de formule (III) est utilisé sous la forme d'un sel d'imidazole.
  11. Procédé selon l'une quelconque des revendications 7 à 10, dans lequel le composé de formule (II) n'est pas isolé sous forme solide.
EP03704541A 2002-02-04 2003-02-03 Procede pour la preparation du propionate de fluticasone,notamment de la forme polymorphe 1 Expired - Lifetime EP1474436B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0202564 2002-02-04
GBGB0202564.1A GB0202564D0 (en) 2002-02-04 2002-02-04 Process
PCT/EP2003/001115 WO2003066653A2 (fr) 2002-02-04 2003-02-03 Nouveau procede

Publications (2)

Publication Number Publication Date
EP1474436A2 EP1474436A2 (fr) 2004-11-10
EP1474436B1 true EP1474436B1 (fr) 2009-10-28

Family

ID=9930366

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03704541A Expired - Lifetime EP1474436B1 (fr) 2002-02-04 2003-02-03 Procede pour la preparation du propionate de fluticasone,notamment de la forme polymorphe 1

Country Status (22)

Country Link
US (1) US20050222107A1 (fr)
EP (1) EP1474436B1 (fr)
JP (1) JP2005517019A (fr)
KR (1) KR20040086331A (fr)
CN (1) CN100338087C (fr)
AR (1) AR038390A1 (fr)
AT (1) ATE446965T1 (fr)
AU (1) AU2003206836B2 (fr)
BR (1) BR0307243A (fr)
CA (1) CA2473896A1 (fr)
CO (1) CO5611115A2 (fr)
DE (1) DE60329824D1 (fr)
GB (1) GB0202564D0 (fr)
IS (1) IS7373A (fr)
MX (1) MXPA04007530A (fr)
NO (1) NO327138B1 (fr)
NZ (1) NZ534320A (fr)
PL (1) PL372214A1 (fr)
RU (1) RU2333218C2 (fr)
TW (1) TW200410982A (fr)
WO (1) WO2003066653A2 (fr)
ZA (1) ZA200405826B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US10174071B2 (en) 2012-05-08 2019-01-08 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL153462A0 (en) * 2002-12-16 2003-07-06 Chemagis Ltd Thiocarboxylic acid organic salts and processes utilizing the same
AU2013202835B2 (en) * 2006-06-14 2015-11-12 Generics [Uk] Limited Process for the preparation of S-fluoromethyl-6,9-difluoro-11-hydroxy-16-methyl-17-propionyloxy-3-oxo-androsta-1, 4-diene-17-carbothioate and intermediates
CA2654644C (fr) 2006-06-14 2014-02-18 Generics [Uk] Limited Nouveau procede et nouveaux intermediaires
JP2013536835A (ja) * 2010-09-01 2013-09-26 カディラ・ヘルスケア・リミテッド プロピオン酸／フロ酸フルチカゾンを調製するための方法
KR20140048237A (ko) 2011-07-08 2014-04-23 화이자 리미티드 플루티카손 프로피오네이트 형태 1의 제조 방법
DE102012221219B4 (de) * 2012-11-20 2014-05-28 Jesalis Pharma Gmbh Verfahren zur Vergrößerung der Partikelgröße kristalliner Wirkstoff-Mikropartikel

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2455976A1 (de) * 1974-11-27 1976-08-12 Merck Patent Gmbh Prostensaeurederivate
PH24267A (en) * 1980-02-15 1990-05-29 Glaxo Group Ltd Androstane carbothioates and pharmaceutical compositions containing the same
US5783677A (en) * 1993-09-24 1998-07-21 Procter & Gamble Pharmaceuticals, Inc. Deoxy and oxygen-substituted sugar-containing 14-aminosteroid compounds
US5488188A (en) * 1994-09-29 1996-01-30 Merrell Dow Pharmaceuticals Inc. Process for the preparation of (E)-1-amino-2-(fluoromethylene)-4-(p-fluorophenyl)butane, novel processes for preparing an intermediate thereof, and novel intermediates thereof
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
GB9925934D0 (en) * 1999-11-03 1999-12-29 Glaxo Group Ltd Novel apparatus and process
EP1305329B2 (fr) * 2000-08-05 2015-03-18 Glaxo Group Limited 6.alpha., 9.alpha.-difluoro-17.alpha.-(2-furanylcarboxyle) oxy-11.beta.-hydroxy-16.alpha.-methyle-3-oxo-androst-1,4-diene-17-acide carbothioique s-fluoromethyle ester utilise comme agent anti inflammatoire

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US10174071B2 (en) 2012-05-08 2019-01-08 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof

Also Published As

Publication number Publication date
US20050222107A1 (en) 2005-10-06
CN100338087C (zh) 2007-09-19
JP2005517019A (ja) 2005-06-09
KR20040086331A (ko) 2004-10-08
IS7373A (is) 2004-07-26
GB0202564D0 (en) 2002-03-20
MXPA04007530A (es) 2004-11-10
CN1642969A (zh) 2005-07-20
AU2003206836B2 (en) 2009-01-08
RU2004122928A (ru) 2005-05-27
CO5611115A2 (es) 2006-02-28
EP1474436A2 (fr) 2004-11-10
CA2473896A1 (fr) 2003-08-14
RU2333218C2 (ru) 2008-09-10
NO20043664L (no) 2004-09-01
WO2003066653A3 (fr) 2003-12-24
ATE446965T1 (de) 2009-11-15
TW200410982A (en) 2004-07-01
WO2003066653A2 (fr) 2003-08-14
NZ534320A (en) 2007-07-27
NO327138B1 (no) 2009-05-04
DE60329824D1 (de) 2009-12-10
AU2003206836A1 (en) 2003-09-02
BR0307243A (pt) 2004-12-14
ZA200405826B (en) 2005-08-11
AR038390A1 (es) 2005-01-12
PL372214A1 (en) 2005-07-11

Similar Documents

Publication Publication Date Title
EP1474436B1 (fr) Procede pour la preparation du propionate de fluticasone,notamment de la forme polymorphe 1
EP2064227A2 (fr) Méthodes de préparation de ciclésonide et sa modification cristalline
EP1301526B1 (fr) Procede d'oxydation pour la preparation de l'intermediaire acide 6 alpha, 9 alpha-difluoro-11 beta,17 alpha-dihydroxy-16.alpha-methyl-androst-1,4-dien-3-one 17 beta-carboxylique
US20070117974A1 (en) One-pot processes for preparing prednisolone derivatives
RU2333217C2 (ru) СПОСОБ ПОЛУЧЕНИЯ 6α, 9α-ДИФТОР-17α-(1-ОКСО-ПРОПОКСИ)-11β-ГИДРОКСИ-16α-МЕТИЛ-3-ОКСО-АНДРОСТ-1,4-ДИЕН-17β-КАРБОТИОНОВОЙ КИСЛОТЫ
US8969547B2 (en) Method for preparing fluticasone furoate
WO2009075776A1 (fr) Procédé pour préparer de la rétapamuline et ses intermédiaires
US20070015836A1 (en) Modafinil synthesis process
CN110317238B (zh) 一种糠酸氟替卡松的制备方法
EP1802647B1 (fr) Procede d'esterification d"un acide carbothioique
US6747163B2 (en) Method for the isolation of 6α, 9α-difluoro-11β, 17α-dihydroxy-16α-methylpregna-3-oxo-1,4-diene-17β-carboxylic acid
CN110128310A (zh) 一种氟维司群中间体

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040722

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1070899

Country of ref document: HK

17Q First examination report despatched

Effective date: 20080620

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: LT LV RO

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60329824

Country of ref document: DE

Date of ref document: 20091210

Kind code of ref document: P

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20091028

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100301

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100208

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091028

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091028

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091028

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091028

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091028

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091028

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091028

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100128

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091028

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091028

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091028

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

26N No opposition filed

Effective date: 20100729

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20100203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100228

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100129

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100228

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100301

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20101029

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100301

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091028

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100203

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1070899

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100429

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091028

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20091028